Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency

Vaccine

Volumn 26, Issue 43, 2008, Pages 5521-5526

  Schenkein, Jeremy G ^a   Park, Saeyoung ^a   Nahm, Moon H ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Efficacy; Streptococcus pneumoniae; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; PNU IMMUNE 23; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; NORMAL HUMAN; OPSONIZATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADULT; AGED; AGING; ANTIBODIES, BACTERIAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 52149084988     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.071     Document Type: Article

References (34)

1. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(RR-8):1-24.
2. Chi R.C., Jackson L.A., and Neuzil K.M. Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia. J Am Geriatr Soc 54 1 (2006) 115-120
3. Pneumococcal vaccines. WHO position paper. Wkly Epidemiol Rec 1999;74(23):177-83.
4. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325 (1991) 1453-1460
5. Schenkein J.G., Nahm M.H., and Dransfield M.T. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest 133 (2008) 767-774
6. Austrian R., Douglas R.M., Schiffman G., Coetzee A.M., Koornhof H.J., Hayden-Smith S., et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 89 (1976) 184-194
7. Smit P., Oberholzer D., Hayden-Smith S., Koornhof H.J., and Hilleman M.R. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 238 24 (1977) 2613-2616
8. Romero-Steiner S., Musher D.M., Cetron M.S., Pais L.B., Groover J.E., Fiore A.E., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody aviditys. Clin Infect Dis 29 (1999) 281-288
9. Rubins J.B., Alter M., Loch J., and Janoff E.N. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 67 11 (1999) 5979-5984
10. Rubins J.B., Puri A.K., Loch J., Charboneau D., MacDonald R., Opstad N., et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 178 2 (1998) 431-440
11. Wernette C.M., Frasch C.E., Madore D., Carlone G., Goldblatt D., Plikaytis B., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 10 4 (2003) 514-519
12. Concepcion N.F., and Frasch C.E. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 8 (2001) 266-272
13. Yu X., Sun Y., Frasch C.E., Concepcion N., and Nahm M.H. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol 6 (1999) 519-524
14. Burton R.L., and Nahm M.H. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 13 9 (2006) 1004-1009
15. Jackson L.A., Neuzil K.M., Nahm M.H., Whitney C.G., Yu O., Nelson J.C., et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 25 20 (2007) 4029-4037
16. Shelly M.A., Schiff G., Smith V., O'Brien D., Nahm M., Germanson T., et al. Evaluation of 9-valent CRM197 conjugated pneumococcal polysaccharide vaccine in elderly adults. ISPPD-4 (2004), Helsinki, Finland p. 231
17. Simberkoff M.S., Cross A.P., Al-Ibrahim M., Baltch A.L., Geiseler P.J., Nadler J., et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 315 21 (1986) 1318-1327
18. Koivula I., Sten M., Leinonen M., and Makela P.H. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 103 4 (1997) 281-290
19. Ortqvist A., Hedlund J., Burman L.A., Elbel E., Höfer M., Leinonen M., et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 351 (1998) 399-403
20. Honkanen P.O., Keistinen T., Miettinen L., Herva E., Sankilampi U., Läärä E., et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 17 20-21 (1999) 2493-2500
21. Yu X., Gray B., Chang S.J., Ward J.I., Edwards K.M., and Nahm M.H. Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants. J Infect Dis 180 (1999) 1569-1576
22. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. MMWR 2007;56(41):1077-80.
23. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination 1998-2004. J Infect Dis 196 9 (2007) 1346-1354
24. Madhi S.A., Kuwanda L., Cutland C., Holm A., Kayhty H., and Klugman K.P. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 24 5 (2005) 410-416
25. Tarrago D., Casal J., Ruiz-Contreras J., Ramos J.T., Rojo P., Snippe H., et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 12 1 (2005) 165-170
26. Nahm M.H., and Romero-Steiner S. Functional assays for pneumococcal antibody. In: Siber G.R., Klugman K.P., and Makela P.H. (Eds). Pneumococcal Vaccines. The impact of conjugate vaccine (2008), ASM Press, Washington, DC 213-226
27. Smithson S.L., Kolibab K., Shriner A.K., Srivastava N., Khuder S., and Westerink M.A. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable light chain repertoire. Infect Immun 73 11 (2005) 7477-7484
28. Kolibab K., Smithson S.L., Rabquer B., Khuder S., and Westerink M.A. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect Immun 73 11 (2005) 7465-7476
29. Yamada E., Tsukamoto Y., Sasaki R., Yagyu K., and Takahashi N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J 14 3 (1997) 401-405
30. Shikata K., Yasuda T., Takeuchi F., Konishi T., Nakata M., and Mizuochi T. Structural changes in the oligosaccharide moiety of human IgG with aging. Glycoconj J 15 7 (1998) 683-689
31. Kobata A. Glycobiology in the field of aging research-introduction to glycogerontology. Biochimie 85 1-2 (2003) 13-24
32. Wright A., Tao M., Kabat E.A., and Morrison S.L. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J. 10 (1991) 2717-2723
33. Kohler H., Bayry J., Nicoletti A., and Kaveri S.V. Natural autoantibodies as tools to predict the outcome of immune response?. Scand J Immunol 58 3 (2003) 285-289
34. Dorshkind K., and Montecino-Rodriguez E. Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol 7 3 (2007) 213-219